01660nas a2200433   4500000000100000008004100001260001300042653001500055653001000070653000900080653003100089653001100120653001300131653001100144653001200155653000900167653003200176653001600208653002500224653003600249653001800285100001200303700001200315700002100327700001500348700001200363700001300375700001500388700001400403700002400417700001200441700001100453245010900464856007200573300001100645490000700656520054900663022001401212       2011                            d  c2011 Jun10aAdolescent10aAdult10aAged10aDrug Resistance, Bacterial10aFemale10agenotype10aHumans10aleprosy10aMale10aMicrobial Sensitivity Tests10aMiddle Aged10aMycobacterium leprae10aPolymorphism, Single Nucleotide10aSouth America1 aSingh P1 aBusso P1 aPaniz-Mondolfi A1 aAranzazu N1 aMonot M1 aHonore N1 aBelone AFF1 aVirmond M1 aVillarreal-Olaya ME1 aRivas C1 aCole S00aMolecular drug susceptibility testing and genotyping of Mycobacterium leprae strains from South America.  uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101379/pdf/zac2971.pdf  a2971-30 v553 a<p>Possible drug resistance in Mycobacterium leprae strains from Venezuela and three other South American countries was surveyed by molecular methods. None of the 230 strains from new leprosy cases exhibited drug resistance-associated mutations. However, two of the three strains from relapsed cases contained dapsone resistance mutations, and one strain also harbored a rifampin resistance mutation. Single nucleotide polymorphism analysis of these strains revealed five subtypes: 3I (73.8%), 4P (11.6%), 1D (6.9%), 4N (6%), and 4O (1.7%).</p>  a1098-6596